Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its late-stage candidate for metabolic dysfunction-associated steatohepatitis (MASH). The $14.50-per-share deal ...
Although Bleach is the flashiest member of the shonen anime “big three,” standing shoulder to shoulder with mega-popular series like One Piece and Naruto, it has long suffered from middle child ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback